Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cubicin for complicated post-surgical wound infections
NCT00651131Phase 4Terminated
- Sponsor
- Merck & Co.
- Start
- Jun 2004
- Primary completion
- Mar 2005
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of daptomycin in surgical site infection (SSI), sponsored by Merck & Co. Primary endpoint: Investigator's assessment of clinical response. Started Jun 2004; status: terminated.
02
Drugs
daptomycin
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on NCT00651131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00651131.